Abstract
The Protein Tyrosine Phosphatase (PTP) family contains not only several promising drug targets, such as PTP1B, but also proteins that are essential to cell development and survival. The availability of sequences and representative structures for the PTP family allows better identification of anti-targets, closely related family members likely to cross-react with directed inhibitors. Eight PTP subfamilies, classified by active site information and overall PTP catalytic domain structure similarity, are reviewed here: 1) the tyrosine-specific PTPs, 2) the dualspecificity PTPs, 3) the cdc25 subclass; 4) the Pten subclass; 5) the myotubularins, 6) the PRL subclass, 7) the low molecular weight PTPs, and 8) the newly defined cdc14 subclass. PTP subfamily classification and structure information can be incorporated into design strategies aimed at identifying potent and selective small molecule inhibitors. The accumulating inhibition data for compounds screened against panels of PTPs is reviewed. The in vitro data can yield clues to specificity so that individual subfamilies can be matched with effective scaffolds to jumpstart lead design and reduce false starts.
Keywords: protein tyrosine phosphatases, ptp, dual-specificity phosphatases, structure-based drug design, inhibitor, specificity
Current Pharmaceutical Design
Title: Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets
Volume: 10 Issue: 10
Author(s): Brian T. Hoffman, Melanie R. Nelson, Keith Burdick and Susan M. Baxter
Affiliation:
Keywords: protein tyrosine phosphatases, ptp, dual-specificity phosphatases, structure-based drug design, inhibitor, specificity
Abstract: The Protein Tyrosine Phosphatase (PTP) family contains not only several promising drug targets, such as PTP1B, but also proteins that are essential to cell development and survival. The availability of sequences and representative structures for the PTP family allows better identification of anti-targets, closely related family members likely to cross-react with directed inhibitors. Eight PTP subfamilies, classified by active site information and overall PTP catalytic domain structure similarity, are reviewed here: 1) the tyrosine-specific PTPs, 2) the dualspecificity PTPs, 3) the cdc25 subclass; 4) the Pten subclass; 5) the myotubularins, 6) the PRL subclass, 7) the low molecular weight PTPs, and 8) the newly defined cdc14 subclass. PTP subfamily classification and structure information can be incorporated into design strategies aimed at identifying potent and selective small molecule inhibitors. The accumulating inhibition data for compounds screened against panels of PTPs is reviewed. The in vitro data can yield clues to specificity so that individual subfamilies can be matched with effective scaffolds to jumpstart lead design and reduce false starts.
Export Options
About this article
Cite this article as:
Hoffman T. Brian, Nelson R. Melanie, Burdick Keith and Baxter M. Susan, Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets, Current Pharmaceutical Design 2004; 10 (10) . https://dx.doi.org/10.2174/1381612043452659
DOI https://dx.doi.org/10.2174/1381612043452659 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design Biomarkers in Post-stroke Depression
Current Neurovascular Research Processing of DNA Replication and Repair Intermediates by the Concerted Action of RecQ Helicases and Rad2 Structure-Specific Nucleases
Protein & Peptide Letters DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews The N-Terminal Region of HIV-1 Tat Protein Binds CD127 in Human CD8 T Cells to Target the Receptor for Down Regulation Through Tat's Basic Region
Current HIV Research Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications
Current Topics in Medicinal Chemistry Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
Current Topics in Medicinal Chemistry The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors
Current Medicinal Chemistry Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets